transcon il-2 β/γ
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT05081609)
Timeline
Indications
Mechanism of action
IL2RA agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05980598 | Phase 2 | Sep 29, 2023 | Ascendis Pharma, Inc. |
| NCT05081609 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Ascendis Pharma, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ascendis Pharma, Inc. | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1